OBJECTIVE To evaluate the incidence and the prevalence of neutralising antibodies (NABs) to three interferon beta (IFNbeta) products in patients with multiple sclerosis (MS). METHODS Sera were tested from 125 patients with relapsing-remitting MS. Patients were treated with IFNbeta-1b (Betaferon, n = 29) 8 MIU subcutaneously every other day, IFNbeta-1a (Avonex, n = 44) 30 microg intramuscularl...

The in vivo immunogenicity of a new interferon (IFN) beta-1a product (Rebif New Formulation; RNF) was compared with that of two approved recombinant human IFN beta-1a products (Rebif and Avonex). Immunogenic potential was assessed based on time to development of neutralizing antibodies (NAbs) and NAb titer. Female BALB/c mice (six in each group) received RNF, Rebif or Avonex (1.0 microg/mL subc...

Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy wit...

Perception and memory of linguistic information is biased in favor of stimuli that conform to structural regularities. At the level of word form, there is evidence that initial consonant clusters varying in grammatical status (e.g., br vs. *bn, *bd, *rb) differentially affect response times in same-different matching (e.g., slower responses to rbif REBIF than to brif BERIF; Berent & Lennertz, 2...

Objective: The primary objective of this study is to describe the disease characteristics of the cohort of MS patients undergoing Rebif treatment. Design: This is a multicentre, open label, non comparative, non randomized study conducted in Egypt on the use of interferon beta-1a (Rebif) therapy in Egyptian patients with relapsing multiple sclerosis according to McDonald criteria. Subjects: Egyp...

BACKGROUND Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels of medication adherence in order to reach acceptable outcomes. The objective of this study was to describe adherence to four disease modifying drugs (DMDs) among statutorily insured patients within two years following treatment initiation. These drugs were interferon beta-1a i.m. (Avo...

BACKGROUND MxA gene expression is one of the most appropriate markers of biological activity of exogenous interferon (IFN) beta. METHODS We quantified MxA mRNA for five consecutive days in 62 patients treated with IFN beta (16, Avonex; 10, Betaferon; 24, Rebif 22; 12, Rebif 44), by quantitative-competitive polymerase chain reaction. Every three months, IFN beta induced neutralising antibodies...

patients and methods in this study, a total of 92 patients with relapsing-remitting multiple sclerosis (rrms) were randomly allocated into three equal groups; each treatment group received one of the foregoing drugs (cinnovexr, rebif and betaferon) for one year. at the beginning and end of the study, patients ‘ edss was measured and compared. results in this study, the relative frequency of fem...